Adaptimmune Therapeutics plc ADR (473A)

Overview

Adaptimmune Therapeutics plc is at the forefront of the battle against cancer, positioning itself as a pivotal player in the clinical-stage biopharmaceutical landscape with a focus on developing novel cell therapies. Founded in 2008, with headquarters in Abingdon, the United Kingdom, the company has expanded its reach to include operations in both the United States and the United Kingdom. Adaptimmune is dedicated to harnessing the power of the body's immune system to fight cancer, spearheading innovative treatments that aim to improve the lives of patients facing this formidable disease. A testament to its pioneering spirit and commitment to excellence, Adaptimmune has forged strategic collaborations with industry giants such as Genentech, Inc., F. Hoffman-La Roche Ltd, Universal Cells, Inc., alongside forming alliances with Noile-Immune, Alpine Immune Sciences, and a strategic agreement with the MD Anderson Cancer Center. These partnerships underline the company's dedication to pushing the boundaries of medical science to unlock new possibilities for cancer treatment.

Products and Services

Adaptimmune is actively engaged in the development of groundbreaking cell therapies targeting various forms of cancer, with key products in different stages of clinical trials:

• SPEARHEAD-1 (Phase II - ADP-A2M4 for Synovial Sarcoma): This development focuses on targeting synovial sarcoma, a rare form of cancer, through a specific cell therapy designed to enhance the body's immune response against tumor cells.
• SURPASS-3 (Phase II - ADP-A2M4CD8 for Platinum Resistant Ovarian Cancer): Aimed at addressing the challenges faced by patients with platinum-resistant ovarian cancer, this therapy leverages modifications to T-cells to attack cancer cells more effectively, offering hope for those with limited treatment options.
• SURPASS (Phase I - Various Cancers including Head and Neck, and Urothelial Cancers): In its initial trial phase, SURPASS aims to evaluate the effectiveness of a novel T-cell therapy across a spectrum of cancers, including those affecting the head and neck, as well as urothelial cancers, showcasing Adaptimmune's dedication to broadening the scope of cancer treatments available.

Additionally, Adaptimmune's strategic collaborations aim to further the development of personalized allogeneic and allogeneic T-cell therapies. These efforts not only underscore the company's innovative approach to cancer treatment but also its commitment to advancing the field of immuno-oncology for the betterment of patient care globally.